Oncolytic Virus Cancer Therapy - Competitive landscape, 2025

Published Date : 2025
Pages : 250
Region : Global,

Share:

oncolytic virus cancer therapy competitive landscape

DelveInsight’s, “Oncolytic Virus Cancer Therapy - Competitive landscape, 2025” report provides comprehensive insights about 85+ companies and 140+ drugs in Oncolytic Virus Cancer Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Oncolytic Virus Cancer Therapy: Understanding

Oncolytic Virus Cancer Therapy: Overview

Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an Oncolytic Virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.

The Oncolytic Virus (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They are able to infect abnormal cells through specific targets, such as nuclear transcription factors and among them human telomerase reverse transcriptase, prostate specific antigen, cyclooxygenase-2, osteocalcin, and surface markers as prostate-specific membrane antigen, folate receptor, CD20, endothelial growth factor receptor, and Her2/neu, which are substances produced by the tumor cells. Furthermore, the deletion of pathogenic viral genes in the laboratory in order to increase the selectivity to the tumor cells and decrease the aggressiveness of the OVs to normal tissues is also possible.

Several criteria are used to objectively determine which virus is optimal in a particular cancer or even a specific patient while choosing Oncolytic Virus Cancer Therapy candidate. There are no general rules for predicting how effective a virus can function as an oncolytic agent. It goes without saying that the candidate virus should not be pathogenic in humans, and not pose a risk to non-human hosts to which a virus could be transmitted. An efficacious Oncolytic Virus Cancer Therapy should not cause any disease, preferentially infect cancer cells over normal cells, efficiently enters cancer cells, should not be hampered by pre-existing anti-viral immune responses, and should kill all cancer cells in an immunogenic manner that induces strong, systemic, and lasting anti-cancer immunity.

Report Highlights

  • In June 2022, Transgene and BioInvent International announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co to evaluate the Oncolytic Virus Cancer Therapy BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.
  • In April 2022, ImmVira announced that, company had reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinical studies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor cobimetinib, to evaluate the safety and efficacy of this combo strategy.
  • In March 2022, Targovax announced a collaboration with Agenus to utilize their proprietary vaccine adjuvant QS-21 STIMULON as an immune-stimulatory component of the TG vaccines for future development and commercialization.
  • In February 2022, Calidi Biotherapeutics, Inc. and Edoc Acquisition Corp. organized to acquire or merge with one or more businesses, have entered into a definitive merger agreement. Upon closing the transaction, anticipated to occur in the second quarter of 2022, the combined company will be named Calidi Biotherapeutics, Inc. and led by Allan Camaisa, CEO and Chairman of the Board. In addition, the combined company’s common stock intends to list on the Nasdaq Capital Market.
  • In January 2022, Transgene and PersonGen BioTherapeutics announced a strategic collaboration to evaluate the feasibility and efficacy of combination therapy associating PersonGen's TAA06 CAR-T cell injection with intravenous (IV) administration of an armed Oncolytic Virus Cancer Therapy, from Transgene’s Invir.IO™ platform, in solid tumors including pancreatic cancer and brain glioma. The collaboration aimed to demonstrate the combination’s likely synergistic mechanisms to potentiate CAR-T cell therapy. Under the terms of the collaboration agreement, Transgene to develop multiple new OV candidates, using its patented Oncolytic Virus Cancer Therapy backbone VVcopTK-RR- and its Invir.IO™ technology platform, specifically for IV administration in combination with PersonGen's TAA06 CAR-T injection. PersonGen to evaluate the efficacy of the combination to eliminate solid tumors in preclinical models.

Oncolytic Virus Cancer Therapy: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to the current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs.

Product Description: DELYTACT

DELYTACT (teserpaturev/G47?), an Oncolytic Virus Cancer Therapy Cancer Therapy developed by the company in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo. DELYTACT has triple mutations within the viral genome that cause augmented and selective replication in cancer cells (third generation oncolytic HSV-1). DELYTACT received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma (a type of malignant glioma) conducted by Dr. Todo. Daiichi Sankyo is pleased to offer DELYTACT as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.

2. Company Overview: Shanghai Pharma Sunway Biotech Co., Ltd.

Established in 1995, Shanghai Pharma Sunway Biotech Co., Ltd. is a wholly-owned innovative pharmaceutical company of SPH. As an R&D-oriented biomedical technology enterprise driven by innovation, its core competence lies in industrialization of drugs in the fields of gene therapy and immunotherapy. As the owner of the first approved gene therapy Oncolytic Virus Cancer Therapy Cancer Therapy in the world, Sunway Bio is committed to promoting and accelerating the development of global medical care with innovative technology and industrialization as the main strategies and through improving the speed and yields of research and production processes and empowering the development and production of innovative drugs.

Product Description: H101

H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory nasopharyngeal cancer, a type of head and neck cancer prevalent in China. This marks the first oncolytic viral therapy approved by any regulatory agency in the world. H101 is a modified adenovirus, a type of common cold virus found in most people. The deletion of an E1B-55kd segment in the virus results in its ability to selectively replicate in and kill tumour cells, while leaving normal cells unaffected. The therapy has a very good safety profile for most patients the main side effect is fever. The SFDA approval is based on a multi-center, randomized parallel-group study comparing 5-fluorouracil and cisplatin-based chemotherapy with and without H101. The H101 study group demonstrated a 27% increase in the number of patients who had complete or partial tumour size reduction compared to the control group, claims a company release.

Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Candel Therapeutics

Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. New discovery programs are based on the HSV platform.

Product Description: CAN-2409

CAN-2409, Candel’s most advanced oncolytic viral immunotherapy product candidate, is a replication-deficient adenoviral gene construct encoding the herpes simplex virus thymidine kinase (HSV-tk) gene. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Intra-tumoral administration results in immunogenic cell death, followed by the release of tumor-specific neoantigens in the tumor microenvironment. At the same time, the adenoviral vector elicits a strong pro-inflammatory signal to the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ cytotoxic T cell-mediated immune response against the injected tumor and the uninjected distant metastases. This dual mechanism of antigen unmasking and immune activation may enable CAN-2409 to generate a powerful and lasting attack against a variety of the patient’s tumor-associated neoantigens, minimizing the possibility for immune escape and development of tolerance. Because of its versatility, CAN-2409 may have the potential to treat a broad range of solid tumors. Encouraging activity has been shown in several preclinical and clinical settings as monotherapy as well as in in combination with standard of care radiation therapy, surgery, chemotherapy, and immune checkpoint inhibitor treatment. Currently the product is in Phase III stage of development for the treatment of Prostate Cancer.

2. Company Overview: CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. The lead candidate, CG0070, is a selective oncolytic immunotherapy which has completed a Phase 2 trial for the treatment of high-grade NMIBC after BCG failure. Additional indications in Muscle-Invasive Bladder Cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, it is aimed to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

Product Description: CG0070

CG0070, a selective oncolytic immunotherapy based on a modified adenovirus type 5 backbone that contains a cancer-selective promoter and a GM-CSF transgene, destroys bladder tumor cells through their defective retinoblastoma (Rb) pathway. CG0070 was designed to replicate inside tumor cells with dysfunctional Rb pathways, causing tumor cell lysis and immunogenic cell death. The rupture of cancer cells releases tumor-derived antigens and GM-CSF, which stimulates a systemic anti-tumor immune response. In advanced clinical trials, CG0070 is a safe and efficacious agent in NMIBC following BCG failure. CG0070 is currently in late-stage clinical trials across a variety of solid cancers, as a monotherapy or in combination with immune checkpoint inhibitors. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Non-Muscular Invasive Bladder Cancer.

3. Company Overview: TILT Biotherapeutics

TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company’s patented TILT® technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor infiltrating lymphocyte (TIL) therapy, and CAR T therapies. TILT’s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase I clinical trials.

Product Description: TILT-123

TILT-123 is the result of years of engineering and testing of ten prototype Oncolytic Virus Cancer Therapy Cancer Therapyes in almost 300 patients in the Advanced Therapy Access Program (ATAP) at the University of Helsinki, Finland. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 is a human 5/3 chimeric adenovirus that has been engineered for targeting, safety and potency. The viral construct includes double selectivity (E2F promoter and D24 deletion in the E1A gene), which means that replication and transgene production are only possible in cancer cells which are uncontrollably dividing and have a high expression of E2F. This is an important safety feature, ensuring that the therapeutic effect is targeted only at cancer cells. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection.

4. Company Overview: Akamis Bio

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn therapeutics anchored by our two clinical stage programs, NG-350A and NG-641. We have an extensive and growing body of clinical experience with T-SIGn® therapeutics with more than 200 patients treated across both the monotherapy setting, as well as in combination with checkpoint inhibitors. Across our clinical studies, T-SIGn therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.

Product Description: NG-347

NG-347 is armed with three transgenes: secreted interferon-a (IFNa), secreted macrophage inflammatory protein-a (MIP1a) and membrane-bound CD80. NG-347 allows IFNa to be expressed directly within the tumor, bypassing the STING pathway. Membrane bound CD80 acts as a costimulatory ligand to enhance T cell activation. KLS 3021 candidate is progressing through preclinical studies in readiness for entering clinical trials.

Further product details are provided in the report……..

Oncolytic Virus Cancer Therapy Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Oncolytic Virus Cancer Therapy Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Oncolytic Virus Cancer Therapy Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Oncolytic Virus Cancer Therapy Report Assessment

  • Company Analysis
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Oncolytic Virus Cancer Therapy drugs?
  • How many Oncolytic Virus Cancer Therapy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oncolytic Virus Cancer Therapy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
  • What are the key designations that have been granted to the emerging and approved drugs?

Tags:

  • Oncolytic Virus Cancer Therapy Pipeline
  • Oncolytic Virus Cancer Therapy clinical trials
  • Oncolytic Virus Cancer Therapy companies
  • Oncolytic Virus Cancer Therapy drugs